Treat Me Right banner

NICE considers new disease modifying treatment for MS

The European Medicines Agency (EMA) has recommended daclizumab, known as Zinbryta, be licensed to treat people with relapsing forms of MS.

The National Institute for Health and Care Excellence (NICE) is now deciding whether to make this treatment available on the NHS in England and Wales.

How does it work?

Daclizumab is injected once a month and works by reducing the number of immune cells thought to contribute to myelin damage seen in MS.

Like all medicines, it can have side effects, but not everybody gets them. Reported side effects of daclizumab include fatigue, stomach upset, infections, and impaired liver function.

Reducing relapses

Data from a phase 3 trial involving 1,841 people with relapsing remitting MS has indicated daclizumab to be more effective than beta-interferons in reducing relapses.

The trial showed after 96 weeks, 73% of participants taking daclizumab were relapse-free, compared to 59% of participants taking beta-interferon.

We need your help

NICE is conducting an appraisal to decide whether daclizumab should be available on the NHS.

We’ll be submitting evidence as part of our Treat Me Right campaign.

We’re calling for all licensed MS treatments to be available on the NHS to everyone eligible for them. We want to hear from you if you’ve been involved in the trials for daclizumab to support our submission to NICE.

>> Email campaigns@mssociety.org.uk to find out how you can get involved